|
KMID : 0378019850280040111
|
|
New Medical Journal
1985 Volume.28 No. 4 p.111 ~ p.116
|
|
|
Clinical Evaluation of Suprofen (Suprol^(®)) in the Treatment of Surgical Patients with pain of Diverse Etiology
|
|
전해명/Jun, Hai Myung
최오규/정상설/김인철/Choi, O Kyu/Jung, Sang Seol/Kim, In Chul
|
|
|
Abstract
|
|
|
As pain is the outstanding symptom of injury and disease and the most frequent reason for a patient to seek medical aid, relief of pain is one of the great objectives in medicine.
Drugs with a predominant pain relieving action are called analgesics and are commonly classified as narcotic and nonnarcotic.
Suprofen is newly developed peripheral acting analgesics with anti-inflammatory and anti-pyretic activities.
This is a clinical report of Suprofen effects on 80 patients with postoperative recurrent cancer and inflammatory pain which were treated with Suprofen 200mg or 400mg b.i.d. for 3-5 days and compared to the effects of Aspirin 650mg b.i.d. and Placebo.
The level of pain relief was evaluated with application of clinical score (0; no relief, I-, a little, 2; good, 3; excellent) and observed it´s clinical efficacy 1,3 and 5 hrs after each dose.
In patients with postoperative pain and pain resulting from inflammatory disease Suprofen 200mg or 400mg b.i.d. was significantly better than Placebo in onset, peak and total effects of pain control and there was no dose related difference between Suprofen 200mg and 400mg b.i.d.
In addition, both doses of Suprofen were better than or at least equivalent to Aspirin 650mg in efficacy.
There was no dramatic analgesic effect in recurrent cancer pain with Suprofen 200mg and Aspirin 650mg b.i.d. But Suprofen 400mg b.i.d. group had some effective control of cancer pain.
Side effects were nearly absent in both group of Suprofen 200mg and 400mg compared´ to Aspirin 650mg b.i.d.
With the above results, Suprofen can be clinically administered as an effective analgesics; for the control of pain with postoperative course and inflammatory disease (200mg b.i.d.) as well as pain with visceral cancer recurrence (400mg b.i.d.).
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|